Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Study provides new insights into breast cancer metastasis

Study provides new insights into breast cancer metastasis

It has long been thought that cancer metastasizes, or spreads, when a single cancer cell escapes from the original tumor, travels through the bloodstream and sets up shop in distant organs. However, a growing body of evidence suggests that these bad actors don't travel alone; instead they migrate through the body in cellular clusters, like gangs. [More]
Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

A team of Georgia State University researchers is fighting cancers using a combination of therapies and recently found ways that radiation could maximize responses to novel immune-based therapeutic approaches to fight cancer. [More]
Overall EU cancer, leukaemia mortality rates to fall in 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia. [More]
Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Severe enterovirus 71 neurological disease in children predominantly involves the spinal cord and brainstem and can be quickly recognised using the World Health Organisation classification of clinicoradiological syndromes, study findings suggest. [More]
VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S. [More]
Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients. [More]
Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. [More]
Sensitive computational method could help reveal effect of the immune system on cancer

Sensitive computational method could help reveal effect of the immune system on cancer

A study by researchers at Norris Cotton Cancer Center has shown that a very sensitive computational method can be used to reveal the human immune system's effect on cancer. The Dartmouth study was the first to perform an in-depth computational examination of how immune activity translates to prognosis in breast cancer. [More]
Researchers explore ways to use light to combat cancer

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals. [More]
MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer. [More]
Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. [More]
Immunotherapy could be the future of cancer treatments

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments." [More]
PD-L1 inhibition well-tolerated, active in metastatic RCC

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings. [More]
TG4010 vaccine promising in advanced NSCLC

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial. [More]
NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019. [More]
Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV. [More]
Quad partners with University of Massachusetts to evaluate performance of novel cell separation solution

Quad partners with University of Massachusetts to evaluate performance of novel cell separation solution

The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood. [More]
Scientists find new way to re-engineer body’s immune system to target cancer

Scientists find new way to re-engineer body’s immune system to target cancer

Scientists have demonstrated a new way of re-engineering the body’s immune system to target cancer, paving the way for a new generation of drugs, unprecedented in safety and effectiveness. [More]
MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina. [More]
Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. [More]
Advertisement